Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors
Expanded collaboration leverages Genmab’s proprietary HexaBody® technology platform to develop novel immunotherapies
First monospecific antibody candidate GEN1053/BNT313 planned to enter clinical trials by the end of 2022
BioNTech and Genmab will share costs and potential future profits on a 50:50 basis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.